Joharatnam-Hogan N, Cafferty F, Hubner R, et al. - Via involving 3,494 candidates (115 in the gastro-oesophageal cancer cohort, 950 in the colorectal cancer cohort, 1,675 in the breast cancer cohort, and 754 in the prostate cancer cohort), researchers presented the preplanned feasibility analysis of the run-in phase of the Add-Aspirin trial to resolve toxicity concerns, especially bleeding after gastro-oesophageal cancer radical treatment. After radical cancer therapy, aspirin was well-tolerated. Toxicity was low and there is no evidence of any discrepancy between the various cancer cohorts in adherence, acceptance of randomization, or toxicity. Trial recruitment continues to decide whether aspirin can provide low-cost potential and well-tolerated treatment to improve cancer outcomes. Overall, dyspepsia was the most frequent grade 1–2 toxicity.